202 related articles for article (PubMed ID: 30625345)
1. Cardioprotective actions of relaxin.
Martin B; Romero G; Salama G
Mol Cell Endocrinol; 2019 May; 487():45-53. PubMed ID: 30625345
[TBL] [Abstract][Full Text] [Related]
2. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
3. Understanding relaxin signalling at the cellular level.
Valkovic AL; Bathgate RA; Samuel CS; Kocan M
Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
[TBL] [Abstract][Full Text] [Related]
4. Relaxin abrogates genomic remodeling of the aged heart.
Romero G; Salama G
Vitam Horm; 2021; 115():419-448. PubMed ID: 33706957
[TBL] [Abstract][Full Text] [Related]
5. Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties.
Beiert T; Knappe V; Tiyerili V; Stöckigt F; Effelsberg V; Linhart M; Steinmetz M; Klein S; Schierwagen R; Trebicka J; Roell W; Nickenig G; Schrickel JW; Andrié RP
Int J Cardiol; 2018 Jan; 250():21-28. PubMed ID: 29169754
[TBL] [Abstract][Full Text] [Related]
6. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
7. Relaxin reverses inflammatory and immune signals in aged hearts.
Martin B; Gabris-Weber BA; Reddy R; Romero G; Chattopadhyay A; Salama G
PLoS One; 2018; 13(1):e0190935. PubMed ID: 29346407
[TBL] [Abstract][Full Text] [Related]
8. New targets for renal interstitial fibrosis: relaxin family peptide receptor 1-angiotensin type 2 receptor heterodimers.
Sasser JM
Kidney Int; 2014 Jul; 86(1):9-10. PubMed ID: 24978374
[TBL] [Abstract][Full Text] [Related]
9. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity.
Praveen P; Wang C; Handley TNG; Wu H; Samuel CS; Bathgate RAD; Hossain MA
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047588
[TBL] [Abstract][Full Text] [Related]
10. Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties.
Beiert T; Tiyerili V; Knappe V; Effelsberg V; Linhart M; Stöckigt F; Klein S; Schierwagen R; Trebicka J; Nickenig G; Schrickel JW; Andrié RP
Biochem Biophys Res Commun; 2017 Aug; 490(3):643-649. PubMed ID: 28634079
[TBL] [Abstract][Full Text] [Related]
11. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
[TBL] [Abstract][Full Text] [Related]
12. The actions of relaxin on the human cardiovascular system.
Sarwar M; Du XJ; Dschietzig TB; Summers RJ
Br J Pharmacol; 2017 May; 174(10):933-949. PubMed ID: 27239943
[TBL] [Abstract][Full Text] [Related]
13. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease.
Samuel CS; Du XJ; Bathgate RA; Summers RJ
Pharmacol Ther; 2006 Nov; 112(2):529-52. PubMed ID: 16814863
[TBL] [Abstract][Full Text] [Related]
14. Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.
Ng HH; Shen M; Samuel CS; Schlossmann J; Bennett RG
Mol Cell Endocrinol; 2019 May; 487():59-65. PubMed ID: 30660699
[TBL] [Abstract][Full Text] [Related]
15. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis.
Samuel CS; Zhao C; Bond CP; Hewitson TD; Amento EP; Summers RJ
Kidney Int; 2004 Jun; 65(6):2054-64. PubMed ID: 15149318
[TBL] [Abstract][Full Text] [Related]
16. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
Grampp S; Goppelt-Struebe M
Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
[TBL] [Abstract][Full Text] [Related]
17. Anti-fibrotic actions of relaxin.
Samuel CS; Royce SG; Hewitson TD; Denton KM; Cooney TE; Bennett RG
Br J Pharmacol; 2017 May; 174(10):962-976. PubMed ID: 27250825
[TBL] [Abstract][Full Text] [Related]
18. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.
Wong SE; Samuel CS; Kelly DJ; Zhang Y; Becker GJ; Hewitson TD
Protein Pept Lett; 2013 Sep; 20(9):1029-38. PubMed ID: 23343143
[TBL] [Abstract][Full Text] [Related]
19. Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
Bani-Sacchi T; Bigazzi M; Bani D; Mannaioni PF; Masini E
Br J Pharmacol; 1995 Sep; 116(1):1589-94. PubMed ID: 8564223
[TBL] [Abstract][Full Text] [Related]
20. Relaxin's physiological roles and other diverse actions.
Sherwood OD
Endocr Rev; 2004 Apr; 25(2):205-34. PubMed ID: 15082520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
